CGNL1

CGNL1 (paracingulin/JACOP) is a cytoplasmic plaque protein of the apical junctional complex that scaffolds the actomyosin and microtubule cytoskeletons to epithelial and endothelial cell-cell junctions (PMID:15292197). It is recruited to tight junctions and to phase-separated ZO-1 condensates through a direct interaction between CGNL1 and the C-terminal ZU5 domain of ZO-1 (PMID:35259394). From this junctional position CGNL1 mechanically couples the cytoskeleton to the membrane: it binds nonmuscle myosins NM2A and NM2B directly through its C-terminal coiled-coil to promote their junctional accumulation and prevent myosin-dependent fragmentation of adherens junctions (PMID:37204781), tethers CAMSAP3-capped microtubule minus-ends to junctions via a coiled-coil interaction to organize cytoplasmic and planar apical microtubules (PMID:37013686), and directly decorates microtubules through a basic stretch in its head domain (residues 365–377) (PMID:39469042). CGNL1 also functions as a spatial organizer of small-GTPase signaling at forming and mature junctions, forming a complex with the Cdc42/Rac GAP SH3BP1 and CD2AP to spatially restrict Cdc42 activity during junction assembly (PMID:22891260), recruiting MgcRacGAP to control Rac1 activation (PMID:24807907), and acting in a ZO-1→CGNL1→p114RhoGEF axis that organizes junctional myosin II tension in endothelial cells (PMID:25753039). In endothelium it stabilizes VE-cadherin–actin linkage and focal adhesion signaling and is required for vascular tubule formation and postnatal retinal neovascular growth (PMID:29016873), and it governs junctional accumulation of claudin-2 (PMID:37566083). In vivo, CGNL1 couples angiotensin II signaling to tubular sodium transporter (NHE3/NCC) activity in the kidney, with loss of CGNL1 protecting mice from angiotensin II–induced hypertension (PMID:40204428).

1. 2004 Medium

   Established that CGNL1 exists as a distinct cingulin-related junctional plaque protein, defining its baseline localization and candidate cytoskeletal-anchoring role.

   Evidence Monoclonal antibody cloning, immunofluorescence, immunoelectron microscopy and overexpression in epithelial/endothelial cells and fibroblasts

   PMID:15292197

   Open questions at the time

   • No direct binding partners identified
   • Anchoring function inferred from overexpression, not loss-of-function
   • No molecular mechanism of recruitment
2. 2012 High

   Resolved how CGNL1 contributes to junction assembly by placing it in a complex that spatially confines Cdc42 activity during membrane remodeling.

   Evidence siRNA screen, reciprocal co-immunoprecipitation, depletion/rescue and junction assembly assays in epithelial cells

   PMID:22891260

   Open questions at the time

   • Direct vs indirect binding within the CGNL1–SH3BP1–CD2AP complex not fully delineated
   • How the complex senses sites of active remodeling unknown
3. 2014 High

   Extended CGNL1's GTPase-regulatory role to Rac1 by showing it recruits MgcRacGAP, while revealing a compensatory expression relationship with cingulin.

   Evidence siRNA knockdown, in vitro direct interaction, co-IP, Rac1 activation and TER assays

   PMID:24807907

   Open questions at the time

   • Mechanism coupling MgcRacGAP recruitment to Rac1 dynamics not detailed
   • Basis of co-regulation of MgcRacGAP expression unresolved
4. 2015 Medium

   Defined a directional endothelial signaling axis (ZO-1→CGNL1→p114RhoGEF) controlling junctional myosin II tension and mechanotransduction.

   Evidence siRNA depletion, FRET tension sensors, immunofluorescence and rescue in endothelial cells

   PMID:25753039

   Open questions at the time

   • Direct CGNL1–p114RhoGEF binding not biochemically established here
   • Single lab
   • RhoA activation step inferred from phenotype
5. 2017 Medium

   Demonstrated an in vivo angiogenic requirement for CGNL1, linking it to VE-cadherin–actin coupling and focal adhesion signaling.

   Evidence 3D co-culture loss-of-function, immunofluorescence, biochemical co-association and postnatal retinal vascular model

   PMID:29016873

   Open questions at the time

   • Direct molecular partners at adherens junctions/focal adhesions not mapped
   • Mechanism linking junctional and focal-adhesion roles unclear
6. 2022 High

   Identified the molecular basis of CGNL1 junctional recruitment via direct binding to the ZO-1 ZU5 domain and to ZO-1 phase-separated condensates.

   Evidence GST pulldown, FRAP, structured illumination microscopy in KO cell lines

   PMID:35259394

   Open questions at the time

   • Functional consequence of condensate partitioning not fully resolved
   • Whether other recruitment routes exist not addressed
7. 2023 High

   Established CGNL1 as a direct actomyosin coupler at junctions by mapping NM2A/NM2B binding to its C-terminal coiled-coil and showing myosin-dependent junction fragmentation upon loss.

   Evidence In vitro direct binding with domain mutagenesis, KO/rescue, immunofluorescence and atomic force microscopy

   PMID:37204781

   Open questions at the time

   • Force regulation dynamics not quantified
   • Interplay with the RhoGEF/GAP modules not integrated
8. 2023 High

   Defined CGNL1 as a microtubule-tethering scaffold by mapping a direct coiled-coil interaction with CAMSAP3 that anchors minus-ends and organizes apical microtubule architecture.

   Evidence KO mouse and cell models, GST pulldown, ultrastructure expansion microscopy

   PMID:37013686

   Open questions at the time

   • How microtubule and actomyosin functions are coordinated unknown
   • Tissue-specific consequences beyond intestine not explored
9. 2023 Medium

   Showed CGNL1 (with cingulin) governs claudin-2 junctional accumulation but is dispensable for overall barrier integrity, refining its role in junction composition.

   Evidence CRISPR KO, TER and dextran permeability, immunofluorescence and rescue in MDCK cells

   PMID:37566083

   Open questions at the time

   • Mechanism linking CGNL1 to claudin-2 localization unknown
   • Redundancy with cingulin not fully separated
10. 2024 Medium

    Demonstrated a direct, autonomous microtubule-binding activity of CGNL1 independent of CAMSAP3, localized to a basic stretch in the head domain.

    Evidence Negative-stain EM, microtubule co-pelleting with recombinant fragments and deletion mutagenesis

    PMID:39469042

    Open questions at the time

    • Cellular significance of direct microtubule binding vs CAMSAP3 tethering not resolved
    • Single in vitro study
11. 2025 Medium

    Connected CGNL1 to organ-level physiology by showing it couples angiotensin II signaling to renal tubular sodium transport and blood pressure control.

    Evidence CGNL1 KO mouse, blood pressure measurement, immunolocalization, transcriptomics, immunoblot and myography

    PMID:40204428

    Open questions at the time

    • Direct molecular link between CGNL1 and NHE3/NCC regulation unknown
    • Whether junctional scaffolding functions underlie the renal phenotype unclear
12. 2026 Low

    Implicated CGNL1 as a modulator of epithelial susceptibility to aflatoxin-induced oxidative stress and immune gene responses.

    Evidence CRISPR KO in porcine IPEC-J2 cells, viability, ROS and RNA-seq

    PMID:42123512

    Open questions at the time

    • Limited mechanistic placement of CGNL1 in oxidative-stress pathways
    • Single lab, non-human cell line
    • No direct molecular target identified

• How CGNL1 integrates its parallel actomyosin coupling, microtubule tethering, and small-GTPase regulatory modules into a unified, spatially coordinated program of junction mechanoregulation remains unresolved.
• No structure of full-length CGNL1 or its multivalent assemblies
• Hierarchy and crosstalk among ZO-1, myosin, CAMSAP3 and GTPase modules not established
• Direct molecular link to renal ion-transport phenotype unknown